Botanix announced a widened product portfolio and progress in its clinical trials as a part of its quarterly activities report.

Botanix Pharmaceuticals (ASX:BOT) announced a widened product portfolio and progress in its clinical trials as a part of its quarterly activities report.

As quoted in the press release:

Key highlights
• Completed BTX 1503 Phase 2 acne clinical study with efficacy and safety results announced in October 2019 (subsequent to quarter end)
• Moving forward with preparations for BTX 1503 Phase 3 clinical program and an end-of Phase 2 meeting with the US FDA
• BTX 1204 Phase 2 atopic dermatitis study entering the final stages, with recruitment on track to be completed in 4Q CY2019 and study data in 1Q CY 2020
• Completed formulation development and pre-clinical studies of BTX 1702 for the treatment of papulopustular rosacea

Click here to read the full press release.

Featured
Global News

Top News

×